SCHEDULE 13D
Explanatory Note:
This joint statement on Schedule 13D/A (this “Statement”) is filed with respect to the Common Stock, par value $0.0001 per share (“Common Stock”), of Tenaya Therapeutics, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 2 (this “Amendment”) supplements and amends the Schedule 13D relating to the Common Stock of the Issuer that was filed with the Commission on December 1, 2022, as amended by Amendment No. 1 filed with the Commission on February 21, 2023 (collectively, the “Original Schedule 13D”), previously reported on a Schedule 13G filed with the Commission on February 11, 2022 (the “Schedule 13G”). The Schedule 13G was filed pursuant to Rule 13d-1(d) of the Securities Exchange Act. This Amendment is being filed to report the purchases by the Reporting Persons of shares of Common Stock as set forth in Item 3 of this Statement. Only those items that are reported are hereby amended; all other items reported in the Original Schedule 13D remain unchanged. Capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items as applicable.
Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Original Schedule 13D is hereby amended by adding the following as the last paragraphs thereof:
On March 10, 2023, TCG Opportunity III LP purchased 6,779 shares of Common Stock for a weighted-average purchase price of $2.5956 per share and an aggregate purchase price of $17,595.57.
On February 12, 2024, TCG Opportunity III LP purchased 2,222,222 shares of Common Stock in the Issuer’s follow-on offering for a purchase price of $4.50 per share (the “February Follow-On Offering”) and an aggregate purchase price of $9,999,999.00.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.
Item 6 of the Original Schedule 13D is hereby amended by adding the following language as the last paragraph thereof:
In connection with the February Follow-on Offering, each of TCG III LP, TCG III-A LP and TCG Opportunity III LP entered into a lock-up agreement, pursuant to which each such party agreed, subject to certain exceptions, not to sell, transfer or otherwise convey certain of the Issuer’s securities held by TCG III LP, TCG III-A LP or TCG Opportunity III LP for 60 days following the date of the final prospectus for the February Follow-on Offering. The terms and provisions of such lock-up agreement are described more fully in the prospectus supplement for the February Follow-on Offering, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 5 to this Statement and is incorporated herein by reference.
Item 7. Material to be Filed as Exhibits.
| | |
Exhibit 5: | | Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (included as Exhibit A to the form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer’s Current Report on Form 8-K as filed with the Commission on February 8, 2024 (SEC File No. 001-40656) and incorporated herein by reference). |